2020
Bengaluru (India)
Series B
Orange Health is a Indian healthtech company in on-demand diagnostics and pathology services. The company address the inefficiencies and delays in traditional diagnostic testing, introducing a model that delivers at-home sample collection within 60 minutes and test results in as little as six hours. Orange Health operates with a vision to make high-quality healthcare diagnostics accessible, reliable and convenient for millions of urban consumers. The company’s proprietary logistics network, in-house eMedic workforce and NABL/ICMR-accredited labs set it apart in a crowded diagnostics market.
At-Home Diagnostic Testing: 60-minute sample collection at home or office, with results delivered in six hours for most tests.
Comprehensive Test Menu: 2,000+ tests including full body checkups, advanced health panels (cardiac, cancer markers), women’s health, allergy and infectious disease diagnostics.
Preventive Health Packages: Curated health checkup packages for individuals and families, tailored to specific health needs and life stages.
Corporate Wellness Solutions: On-site and at-home health checkups for 200+ corporate clients, serving over 30,000 employees across major metros.
Digital Health Platform: App and web-based booking, digital report delivery and AI-driven health insights for personalized care.
National Reference Laboratory: Advanced testing capabilities, including maternal markers and genomics, with gold-standard platforms for accuracy.
Diagnostic Services: Revenue from individuals and businesses paying for tests and health packages.
Corporate Partnerships: Work with companies to provide employee health checkups and wellness programs.
Subscriptions & Preventive Care: Recurring income from annual health plans and preventive care services.
Geographic Expansion: Currently in Bengaluru, Delhi-NCR, Mumbai and Hyderabad — targeting 15 cities by 2027.
$47.1 Million
3
$12 Million, Series B
as of December 6, 2024
-
as of N/A
-
as of N/A
Accel
and 2 more499
Curelo
N/A
Date | Round Name | Amount | Valuation | Revenue | Revenue Multiple | Investors |
---|---|---|---|---|---|---|
December 6, 2024 | Series B | $12 Million | - | - | - | ASVF, Accel, General Catalyst, Bertelsmann India Investments, Y Combinator |
May 31, 2022 | Series B | $25 Million | - | $3 Million | - | Bertelsmann India Investments, General Catalyst, Accel, Y Combinator, Good Capital, Uncorrelated Ventures |
October 1, 2021 | Series A | $25 Million | - | $1.9 Million | - | Accel |